Le Lézard
Classified in: Health
Subject: CCA

Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2019 Results Presentation and Webcast


OSLO, Norway, Aug. 16, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the second quarter and first half 2019 on Thursday, 22 August 2019.

A presentation by Nordic Nanovector's senior management team will take place at 8:30am CEST at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: AKER

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CEST the same day.

For further information, please contact: 

IR enquiries

Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com  

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com  

About Nordic Nanovector: 

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-second-quarter-and-first-half-2019-results-presentation-and-web,c2882117

SOURCE Nordic Nanovector


These press releases may also interest you

at 02:00
Chronic kidney disease affects 1 out of 10 people worldwide and is steadily increasing. When it reaches end-stage renal disease and endangers the lives of patients, dialysis or transplantation is required. Renal transplantation is the treatment of...

20 sep 2019
SymbioCellTech, LLC , a biotechnology company in Salt Lake City pioneering stem cell therapy for diabetes and associated auto-immune disorders and microvascular conditions, today announced the online journal PLOS ONE published interim data...

20 sep 2019
Dr. Jason Emer of Emerage Medical is globally recognized as one of the most cutting-edge, board-certified dermatologist and cosmetic surgeons in the field of advanced dermatology, plastic surgery and body contouring. Continuing his passion and...

20 sep 2019
The Florida Medical Cannabis Conference & Exhibition (FMCCE 2020) will be held June 26 - 28, 2020, at the Naples Grand Beach Resort in Naples, Florida.  This conference is a networking and educational forum on the subject of medical cannabis. This...

20 sep 2019
Monday, September 23 is the first day of Fall, with its crisp mornings, warm afternoons and trees arrayed in canopy coats of brilliant orange, red and yellow leaves. The first day of Fall is also the beginning of Fall Prevention Awareness Week,...

20 sep 2019
WHO: Merritt Pember, M.D., Direct Orthopedic Care (DOC) Surgeon and Veteran U.S. Army Major (Operation Iraqi Freedom)  Major Dan Rooney, Founder, Folds of Honor WHAT: Run for the Flag Race WHEN: Saturday, November 2, 2019 9 a.m. to 12 noon CT WHERE:...



News published on 16 august 2019 at 02:14 and distributed by: